Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.

INTERVENTION: Trade Name: CARDURA Product Name: DOXAZOSIN Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: MONOCOR Product Name: BISOPROLOL Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: ZESTRIL Product Name: LISINOPRIL Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: ISTIN Product Name: AMLODIPINE Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: AMIAS Product Name: CANDESARTAN Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: APRINOX Product Name: BENDROFLUMETHIAZIDE Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use CONDITION: Polycystic kidney disease PRIMARY OUTCOME: Main Objective: To identify best antihypertensive agent to control blood pressure Primary end point(s): FALL IN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE Secondary Objective: INCLUSION CRITERIA: • patients who have given informed consent • male or female patients aged 18‐65 years inclusive • normal renal function: defined as a creatinine clearance (ml/min/1.73m2) of >=85 in men and >=75 in women • either treated hypertensives on antihypertensive medication (no more than 2 agents) or untreated patients in whom initiation of treatment will follow the 1999 British Hypertension Society guidelines19 i.e. a seated BP >160/100, OR >140/90 with either end‐organ changes or 10‐year CHD risk of >15% Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range